'Jupiter trial' diaporamas de présentation

Aspirin and Statins for primary prevention What is new and d oes gender really matters ?

Aspirin and Statins for primary prevention What is new and d oes gender really matters ?. Dr Tali Porter , Head of intermediate ICCU - Dept. of Cardiology, Rabin Medical Center- Belinson Campus, Petah Tikva, Tel Aviv University. Case presentation. - Statins.

826 views • 64 slides

A Randomized Trial of Rosuvastatin in the Prevention

A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial Paul Ridker, Eleanor Danielson, Francisco Fonseca, Jacques Genest,

715 views • 56 slides

A Randomized Trial of Rosuvastatin in the Prevention

A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial Paul Ridker, Eleanor Danielson, Francisco Fonseca, Jacques Genest,

918 views • 55 slides

A Randomized Trial of Rosuvastatin in the Prevention

JUPITER Trial Presented during AHA 2008 Scientific Sessions. A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial

754 views • 54 slides

A Randomized Trial of Rosuvastatin in the Prevention

JUPITER Trial Presented during AHA 2008 Scientific Sessions. A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial

744 views • 54 slides

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death. Placebo 251/8901. HR 0.56, 95% CI 0.46-0.69 P <0.00001. 0.08. 0.06. - 44 %. Cumulative Incidence. 0.04. Rosuvastatin 142 / 8901. 0.02. 0.00. 0. 1. 2. 3. 4. Follow-up (years). Number at Risk.

830 views • 54 slides

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death. Placebo 251/8901. HR 0.56, 95% CI 0.46-0.69 P <0.00001. 0.08. 0.06. - 44 %. Cumulative Incidence. 0.04. Rosuvastatin 142 / 8901. 0.02. 0.00. 0. 1. 2. 3. 4. Follow-up (years). Number at Risk.

546 views • 54 slides

A Randomized Trial of Rosuvastatin in the Prevention

JUPITER Trial Presented during AHA 2008 Scientific Sessions. A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial

557 views • 54 slides

A Randomized Trial of Rosuvastatin in the Prevention

JUPITER Trial Presented during AHA 2008 Scientific Sessions. A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial

559 views • 54 slides

527 views • 40 slides

JUPITER AHA November 9, 2008

JUPITER AHA November 9, 2008. Ridker - 162. A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial

360 views • 12 slides

JUPITER AHA November 9, 2008

JUPITER AHA November 9, 2008. Ridker - 162. A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women With Elevated Levels of C-Reactive Protein (hsCRP): The JUPITER Trial

123 views • 12 slides